Long term therapy of generalized anxiety disorder

European Psychiatry

Volumn 19, Issue 2, 2004, Pages 96-101

  Rouillon, Frédéric ^a  

^a Hopital Albert Chenevier   (France)

Author keywords

GAD; Long term; Pharmacotherapy; Psychosocial treatment

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; AZAPIRONE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMAZEPAM; BUSPIRONE; CHLORDIAZEPOXIDE; CLORAZEPATE; DELORAZEPAM; DIAZEPAM; FLUVOXAMINE; HYDROXYZINE; IMIPRAMINE; IPSAPIRONE; LORAZEPAM; NEFAZODONE; OPIPRAMOL; PAROXETINE; PREGABALIN; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUBSTANCE P ANTAGONIST; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ADDICTION; ANOREXIA; ARTICLE; ATAXIA; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; LONG TERM CARE; META ANALYSIS; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOTHERAPY; RECURRENT DISEASE; RELAXATION TRAINING; SEDATION; SIDE EFFECT; SOCIAL ASPECT; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; COGNITIVE THERAPY; HUMANS; PSYCHOTHERAPY; TIME;

EID: 1642465483     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2004.01.001     Document Type: Article

References (78)

1. Allgulander C., Hackett D., Salinas E. Venlafaxine extended-release (ER) in the treatment of generalized anxiety disorder. Twenty-four week placebo controlled dose ranging study. Brit J Psychiatry. 179:2001;15-22.
2. Allgulander C., Hirschfeld R.M., Nutt D.J. Long-term treatment strategies in anxiety disorders. Psychopharmacol Bull. 36:(Suppl 2):2002;79-92.
3. Ballenger J.C. Clinical guideslines for establishing remission in patients with depresssion and anxiety. J Clin Psychiatry. 60:(Suppl 22):1999;29-34.
4. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Borkovec T.D., Rickels K., et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 62:(Suppl 11):2001;53-58.
5. Barlow D.H. Anxiety and its disorders. 1988;Guiford Press, New York.
6. Barlow D.H., Cohen A.S., Waddell M.T., Vermilyea B.B., Kosco J.S., Blanchard E.B., et al. Panic and generalized anxiety disorders: nature and treatment. Behav Ther. 15:1984;431-449.
7. Barlow D.H., Rapee R., Brown T.A. Behavioral treatment of generalized anxiety disorder. Behav Ther. 23:1992;551-570.
8. Beck A.T., Hemery G. Anxiety disorders and phobias: a cognitive perspective. 1985;Basic Books, New York.
9. Blowers C., Cobb J., Mathews A. Generalized anxiety: a controlled treatment study. Behav Res Ther. 25:(6):1987;493-502.
10. Borison R.L., Albrecht J.W., Diamond B.I. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull. 26:1990;207-210.
11. Borkovec T.D., Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 61:(4):1993;611-619.
12. Borkovec T.D., Mathews A.M. Treatment of nonphobic anxiety disorders: a comparison of nondirective cognitive and desensitization therapy. J Consult Clin Psychol. 56:(6):1988;877-884.
13. Borkovec T.D., Mathews A.M., Chambers A., Ebrahimi S., Lytle R., Nelson R. The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of anxiety generalized anxiety. J Consult Clin Psychol. 55:1987;833-883.
14. Borkovec T.D., Whisman M. Psychosocial treatment for GAD. Mavissakalian M., Prien R.F. Long-term treatment for anxiety disorders. 1996;171-199 American Psychiatric Press, Washington (DC).
15. Borkovec T.D., Ruscio A.M. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 62:(Suppl 11):2001;43-45.
16. Boyer P., Mahé V., Hackett D., et al. Efficacy of venlafaxine ER in social adjustment in patients with GAD. Presented at the 13th Annual Meeting of the ECNP Congress, Munich, 9-13 September 2000:2000.
17. Boyer W.F., Feighner J.P. A placebo controlled double blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorders. Int Clin Psychopharmacol. 8:1993;173-176.
18. Buttler G., Cullington A., Hibert G., Klimes I., Gelder M. Anxiety managment for persistent generalized anxiety. Brit J Psychiatry. 151:1987;535-542.
19. Butler G., Fennel M., Robson P., Gelder M. Comparison of behaviour therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 59:(1):1991;167-175.
20. Cohn J.B., Wilcox C.S. Long-term comparison of alprazolam, lorazepam and placebo in patients with anxiety disorder. Psychopharmacotherapy. 4:1984;93-98.
21. Cutler N.R., Sramek J.J., Hesselink J.M.K., Krol A., Roeschen J., Rickels K., et al. A double blind, placebo controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol. 13:1993;429-437.
22. Davidson J.R.T., Dupont R.L., Hedges D., Haskins J.T. Efficacy, safety and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 60:1999;528-535.
23. Dugas M.J., La Douceur R. Treatment of GAD targeting intolerance of uncertainty in two types of worry. Behav Modif. 24:2000;635-637.
24. Durham R.C., Chambers J.A., McDonald R.R., Power K.G., Major K. Does cognitive-behavioral therapy influence the long-term outcome of generalized anxiety disorder? An 18-14 years follow-up of two clinical trials. Psychol Med. 33:2003;499-509.
25. Durham R.L., Murphy T., Allan T., Richard K., Treliving L.R., Fenton G.W. Cognitive therapy, analytic psychotherapy and anxiety management training for generalized anxiety disorder. Brit J Psychiatry. 165:1994;315-323.
26. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology. 105:1991;428-432.
27. Feighner J.B. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 48:(Suppl 12):1987;3-6.
28. Feighner J.B., Cohn J.B. Analysis of individual symptoms in generalized anxiety: a pooled multistudy double blind evaluation of buspirone. Neuropsychobiology. 21:1989;124-130.
29. Ferreri M., Hantouche E., Billardon M. Advantages of hydroxyzine in generalized anxiety disorder: a double blind controlled versus placebo study. L'Encéphale. 20:1994;785-791.
30. Figueira M.L. Alprazolam ER in the treatment of generalized anxiety: a multicentre controlled study with bromazepam. Hum Psychopharmacol Clin Exp. 14:1999;171-177.
31. Fisher P.L., Durham R.C. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med. 29:1999;1425-1434.
32. Floyd M., McKendree-Smith N., Stump J., Scogin F., Bowman D. Two-year follow-up of self examination therapy for generalized anxiety disorder. J Anxiety Disord. 16:(4):2002;369-375.
33. Gelenberg A.J., Lydiard R.B., Rudolph R.L., Aguiar L., Haskins J.T., Salinas E. Efficacy of venlafaxine extended-release capsules in non depressed outpatients with generalized anxiety disorder. A 6 month randomized controlled trial. JAMA. 283:2000;3082-3088.
34. Goisman R.M., Warsham M.G., Keller M.B. Psychosocial treatment prescriptions for generalized anxiety disorder panic disorder and social phobia 1991-1996. Am J Psychiatry. 156:(11):1999;1819-1821.
35. Hedges D.W., Reimherr F.W., Strong R.E., Halls C.H., Rust C. An open trial of nefazodone in adult patients with GAD. Psychopharmacol Bull. 32:1996;671-676.
36. Hoehn-Saric R., Mc Leod D.R., Zimmerli W.D. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 49:1988;293-301.
37. Kahn R.J., Mc Nair D.M., Lipman R.S., Covi L., Rickels K., Downing R., et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders II: efficacy in anxious outpatients. Arch Gen Psychiatry. 43:1986;79-85.
38. Katz I.R., Reynolds C.F.I., Alexopoulos G.S., Hackett D. Venlafaxine (ER) as a treatment for generalized anxiety disorder in older adults: a pooled analysis of 5 randomized placebo controlled clinical trials. J Am Geriat Soc. 50:2002;18-25.
39. Keller M.B. Raising the expectations of long term treatment strategies in anxiety disorders. Psychopharmacol Bull. 36:(Suppl 2):2002;166-174.
40. Kessler R.C., Mc Gonagle K.A., Zhao K.A., Nelson C.R., Hughis M., Eshlenan, et al. Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the USA: results from the National Comorbidity Survey. Arch Gen Psychiatry. 51:1994;8-19.
41. Klein E., Colin V., Stolk J., Lennox R.H. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry. 151:1994;1760-1766.
42. Kupfer D.J., Franck E. The interaction of drug and psychotherapy in the long term treatment of depression. J Affective Disord. 62:2001;131-137.
43. Lader M., Scotto J.C. A multicentre double blind comparison of hydroxyzine buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology. 139:1998;402-406.
44. La Douceur R., Dugas M.J., Freeston M.H., Leger E., Gagnont F., Thibodeau N. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. J Consult Clin Psychol. 68:2000;957-965.
45. Léger E., La Douceur R., Dugas M.J., Freeston M.H. Cognitive-behavioral treatment of generalized anxiety disorder among adolescents: a case series. J Am Acad Child Adolesc Psychiatry. 42:(3):2003;327-330.
46. Llorca P.M., Spadone C., Sol O., Danniau A., Bougerol T., Corruble E., et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3 months double blind study. J Clin Psychiatry. 63:2002;1020-1027.
47. Maier W., Gaensicke M., Freyberger H.J., Linz M., Lecrubier Y. Generalized anxiety disorder (I.C.D.10) in primary care from a cross cultural perspective. A valid diagnostic entity? Acta Psychiat Scand. 101:2000;29-36.
48. Manassis K., Mendlowitz S.L., Scapillato D., Avery D., Fiksenbauml L., Freire M., et al. Group and individual cognitive-behavioral therapy for chilhoud anxiety disorders: a randomized trial. J Am Acad Child Adolesc Pschiatry. 41:2002;1423-1430.
49. Mohlman J., Gorenstein E.E., Kleber M., De Jesus M., Gorman J.M., Papp L.A. Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry. 11:(1):2003;24-32.
50. Möller H.J., Volz H.P., Reimann I.W., et al. Opipramol for the treatment of generalized anxiety disorder: a placebo controlled trial including an alprazolam-treatment group. J Clin Psychopharmacol. 21:2001;59-65.
51. Montgomery S.A., Sheehan D.V., Meoni P., Haudiquet V., Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long term treatment with venlafaxine XRJ. Psychiatry Res. 36:(3):2002;209-217.
52. Morselli P.L. On the therapeutic action of alpidem in anxiety disorders: an overview of European data. Pharmacopsychiatry. 23:(Suppl):1990;129-134.
53. Murphy S.M., Owen R., Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks treatment with diazepam or buspirone. Br J Psychiatry. 154:1989;529-534.
54. Ninan P.T. Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry. 62:(Suppl 19):2001;5-10.
55. Pande A.C., Crockatt J.G., Feltner D.E., Janney C.A., Smith W.T., Weisler R., et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 160:(3):2003;533-540.
56. Pelissolo A., André C., Chignon J.M., Dutoit D., Martin P., Richard-Berthe C., et al. Anxiety disorders in private practice psychiatric outpatients: prevalence comorbidity and burden. L'Encéphale. 28:2002;510-519.
57. Pollack M.H., Zaninelli R., Godard A., Mc Cafferty J.P., Bellew K.M., Burnham D.B., et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled flexible dosage trial. J Clin Psychiatry. 62:2001;350-357.
58. Power K.G., Simpson R.J., Swanson V., Wallace L.A. (a) Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Brit J Gen Pract. 40:1990;289-294.
59. Power K.G., Simpson R.J., Swanson V., Wallace L.A., Feistner A.T.C., Sharp D.A. A controlled comparison of cognitive-behaviour therapy, diazepam and placebo alone and in combination for the treatment of generalized anxiety disorder. J Anxiety Disord. 4:1990;267-292.
60. Rakel R.E. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J. 83:(2):1990;195-198.
61. Rickels K., Case W.G., Downing R.W., Winokur A. Long term diazepam therapy and clinical outcome. JAMA. 250:1983;767-771.
62. Rickels K., Downing R., Schweizer E., Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry. 50:1993;884-895.
63. Rickels K., Schweizer E., Canalosi I., Case W.G., Chung H. Long term treatment of anxiety and risk of withdrawal: a prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 45:1988;445-450.
64. Rickels K., Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 63:(Suppl 14):2002;9-16.
65. Rocca P., Fonzo V., Scotta M., Zanalda E., Ravizza L. Paroxetine efficacy in the treatment of GAD. Acta Psychiatr Scand. 95:(5):1997;445-450.
66. RUPPASG (Research Unit on Pediatric Psychopharmacology Anxiety Study Group). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. Engl J Med. 344:2001;1279-1285.
67. Rynn M.A., Siqueland L., Rickels K. Placebo-controlled trial of sertraline in the children with GAD. Am J Psychiatry. 158:2001;2008-2014.
68. Schweizer E., Rickels K. The long-term management of generalized anxiety disorder: issues and dilemmas. J Clin Psychiatry. 57:(Suppl 7):1996;9-12.
69. Shader R.I., Greenblatt D.J. Use of benzodiazepines in anxiety disorders. N Engl J Med. 328:1993;1398-1405.
70. Shader R.I., Greenblatt D.J. Use of benzodiazepines in anxiety disorders. N Engl J Med. 328:1993;1398-1405.
71. Sheehan D.V., Raj A.B., Harnett-Sheehan K., Soto S., Knapp E. The relative efficacy of high-dose buspirone and alprazolamin the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand. 89:1993;1-11.
72. Stocchi F., Nordera G., Jokinen R., et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin Psychiatry. 64:2003;250-258.
73. Varia I., Rauscher F. Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 17:(3):2002;103-107.
74. Westen D., Morrison K. A multidimensional meta analysis of treatments for depression, panic and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol. 69:2001;875-899.
75. Wetherell J.L., Gatz M., Craske M.G. Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol. 71:(1):2003;31-40.
76. Wittchen H.U., Kessler R.C., Pfister H., Lieb M. Why do people with anxiety disorders become depressed? A prospective longitudinal community study. Acta Psychiatr Scand. 102:(Suppl 406):2000;14-23.
77. Yonkers K.A., Warshaw M., Massion A.O., Keller M.B. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry. 168:1996;308-311.
78. Yonkers K.A., Dick I.R., Warshaw M., Keller M.B. Factors predicting the clinical course of generalized anxiety disorder. Brit J Psychiatry. 176:2000;544-549.